INM
InMed Pharmaceuticals Inc.
Price Chart
Latest Quote
$1.52
-0.03 (-1.92%)
Current Price
| Previous Close | $1.55 |
| Open | $1.53 |
| Day High | $1.57 |
| Day Low | $1.52 |
| Volume | 5,859 |
Stock Information
| Shares Outstanding | 3.31M |
| Total Debt | $420K |
| Cash Equivalents | $5.20M |
| Revenue | $4.94M |
| Net Income | $-7.84M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $5.04M |
| EPS (TTM) | $-1.47 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $356K |
| Sales | $4.94M |
| Income | $-7.84M |
| Book/sh | $2.08 |
| Cash/sh | $1.57 |
| Employees | 13 |
Financial Ratios
| Quick Ratio | 2.35 |
| Current Ratio | 3.12 |
| Debt/Eq | 6.10 |
Returns & Margins
| ROA | -54.61% |
| ROE | -112.65% |
| Gross Margin | 34.53% |
| Operating Margin | -162.75% |
| Profit Margin | -172.17% |
Ownership
| Insider Ownership | 0.12% |
| Institutional Ownership | 69.87% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.24 |
| P/S | 1.02 |
| P/B | 0.73 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $1.54 |
| SMA50 | $1.15 |
| SMA200 | $1.32 |
| RSI | 44.47 |
| ATR | 0.0736 |
| Shares Float | 788K |
| Short Float | 4.07% |
| Short Ratio | 0.03 |
| Volatility | 0.97 |
| Rel Volume | 0.07 |
Performance History
| Week | +2.03% |
| Month | -11.62% |
| Quarter | +117.48% |
| 6 Months | +21.62% |
| YTD | +35.73% |
| Year | -60.72% |
| 3 Years | -93.45% |
| 5 Years | -99.90% |
| 10 Years | -99.88% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $1.52 | 5,859 |
| 2026-06-24 | $1.55 | 47,700 |
| 2026-06-23 | $1.50 | 7,300 |
| 2026-06-22 | $1.50 | 34,300 |
| 2026-06-18 | $1.49 | 26,200 |
| 2026-06-17 | $1.49 | 18,700 |
| 2026-06-16 | $1.48 | 27,300 |
| 2026-06-15 | $1.51 | 36,100 |
| 2026-06-12 | $1.51 | 39,500 |
| 2026-06-11 | $1.58 | 30,700 |
| 2026-06-10 | $1.51 | 42,000 |
| 2026-06-09 | $1.53 | 67,800 |
| 2026-06-08 | $1.54 | 147,400 |
| 2026-06-05 | $1.58 | 206,500 |
| 2026-06-04 | $1.56 | 92,800 |
| 2026-06-03 | $1.59 | 89,500 |
| 2026-06-02 | $1.52 | 156,900 |
| 2026-06-01 | $1.56 | 198,700 |
| 2026-05-29 | $1.57 | 200,300 |
| 2026-05-28 | $1.68 | 93,200 |
| 2026-05-27 | $1.66 | 279,700 |
| 2026-05-26 | $1.72 | 345,100 |
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with unmet medical needs. The company's lead product consists of INM-755, a cannabinol topical skin cream that has completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, a small molecule compound that acts as a selective dual CB1/CB2 agonist; and INM-900 for neurodegenerative diseases, as well as INM-901, a small molecule for treatment of Alzheimer's disease. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
đ° Latest News
InMed-Mentari Migraine Merger Backed by $290 Million Financing Reshapes Company Strategy (INM)
InvestorsHub âĸ 2026-05-19T14:37:16Z
A migraine drugmaker heads to the public markets through reverse merger
BioPharma Dive âĸ 2026-05-19T11:19:00Z
InMed Pharmaceuticals reports FY25 EPS ($8.36) vs ($20.14) last year
TipRanks âĸ 2025-09-24T12:45:20Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $2,914,161 | $3,111,899 | $2,338,777 | $219,759 |
| Cost Of Revenue | $3,236,047 | $3,496,817 | $2,732,525 | $545,889 |
| Total Revenue | $4,942,633 | $4,597,730 | $4,135,561 | $1,089,435 |
| Operating Revenue | $4,942,633 | $4,597,730 | $4,135,561 | $1,089,435 |
| Expenses | ||||
| Interest Expense | $371,549 | $0 | - | $0 |
| Total Expenses | $12,860,628 | $12,732,160 | $12,514,348 | $14,881,191 |
| Other Income Expense | $-28,471 | $-61,921 | $-48,175 | $-4,904,451 |
| Net Non Operating Interest Income Expense | $-215,667 | $527,901 | $492,440 | $96,090 |
| Interest Expense Non Operating | $371,549 | $0 | - | $0 |
| Operating Expense | $9,624,581 | $9,235,343 | $9,781,823 | $14,335,302 |
| General And Administrative Expense | $6,557,822 | $5,798,226 | $5,847,518 | $6,867,030 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-8,162,133 | $-7,675,550 | $-7,947,622 | $-18,600,117 |
| Net Interest Income | $-215,667 | $527,901 | $492,440 | $96,090 |
| Interest Income | $155,882 | $527,901 | $492,440 | $96,090 |
| Normalized Income | $-8,133,662 | $-7,622,917 | $-7,918,717 | $-13,695,666 |
| Net Income From Continuing And Discontinued Operation | $-8,162,133 | $-7,675,550 | $-7,947,622 | $-18,600,117 |
| Net Income Common Stockholders | $-8,162,133 | $-7,675,550 | $-7,947,622 | $-18,600,117 |
| Net Income | $-8,162,133 | $-7,675,550 | $-7,947,622 | $-18,600,117 |
| Net Income Including Noncontrolling Interests | $-8,162,133 | $-7,675,550 | $-7,947,622 | $-18,600,117 |
| Net Income Continuous Operations | $-8,162,133 | $-7,675,550 | $-7,947,622 | $-18,600,117 |
| Pretax Income | $-8,162,133 | $-7,668,450 | $-7,934,522 | $-18,600,117 |
| Interest Income Non Operating | $155,882 | $527,901 | $492,440 | $96,090 |
| Operating Income | $-7,917,995 | $-8,134,430 | $-8,378,787 | $-13,791,756 |
| Depreciation Amortization Depletion Income Statement | $212,839 | $219,600 | $202,249 | $185,657 |
| Depreciation And Amortization In Income Statement | $212,839 | $219,600 | $202,249 | $185,657 |
| Gross Profit | $1,706,586 | $1,100,913 | $1,403,036 | $543,546 |
| Special Income Charges | - | - | $0 | $-3,472,593 |
| Per Share | ||||
| Diluted EPS | $-8.36 | $-20.20 | $-65.00 | $-663.40 |
| Basic EPS | $-8.36 | $-20.20 | $-65.00 | $-663.40 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $-9,288 | $-19,270 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-7,227,388 | $-7,002,011 | $-7,734,615 | $-8,375,518 |
| Total Unusual Items | $-28,471 | $-61,921 | $-48,175 | $-4,904,451 |
| Total Unusual Items Excluding Goodwill | $-28,471 | $-61,921 | $-48,175 | $-4,904,451 |
| Reconciled Depreciation | $534,725 | $604,518 | $595,997 | $511,787 |
| EBITDA (Bullshit earnings) | $-7,255,859 | $-7,063,932 | $-7,782,790 | $-13,279,969 |
| EBIT | $-7,790,584 | $-7,668,450 | $-8,378,787 | $-13,791,756 |
| Diluted Average Shares | $975,985 | $381,053 | $122,422 | $28,041 |
| Basic Average Shares | $975,985 | $381,053 | $122,422 | $28,041 |
| Diluted NI Availto Com Stockholders | $-8,162,133 | $-7,675,550 | $-7,947,622 | $-18,600,117 |
| Tax Provision | $0 | $7,100 | $13,100 | $0 |
| Gain On Sale Of Security | $-28,471 | $-61,921 | $-48,175 | $-1,431,858 |
| Research And Development | $2,853,920 | $3,217,517 | $3,732,056 | $7,282,615 |
| Selling General And Administration | $6,557,822 | $5,798,226 | $5,847,518 | $6,867,030 |
| Other Gand A | $6,557,822 | $5,798,226 | $5,847,518 | $6,867,030 |
| Impairment Of Capital Assets | - | - | $0 | $3,472,593 |
Fetched: 2026-06-25
Balance Sheet (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $11,813,933 | $7,422,911 | $10,143,448 | $6,969,626 |
| Total Assets | $15,580,040 | $11,822,782 | $14,106,340 | $12,787,580 |
| Total Non Current Assets | $2,712,761 | $3,133,197 | $2,774,613 | $3,189,804 |
| Other Non Current Assets | $100,000 | $100,000 | $104,908 | $176,637 |
| Goodwill And Other Intangible Assets | $1,620,562 | $1,783,198 | $1,946,279 | $2,108,915 |
| Other Intangible Assets | $1,620,562 | $1,783,198 | $1,946,279 | $2,108,915 |
| Current Assets | $12,867,279 | $8,689,585 | $11,331,727 | $9,597,776 |
| Other Current Assets | $321,747 | $477,749 | $498,033 | $797,225 |
| Restricted Cash | $43,384 | $43,064 | $44,422 | $44,804 |
| Inventory | $961,173 | $1,244,324 | $1,616,356 | $2,490,854 |
| Receivables | $465,104 | $352,838 | $260,399 | $88,027 |
| Accounts Receivable | $465,104 | $352,838 | $260,399 | $88,027 |
| Allowance For Doubtful Accounts Receivable | $-2,424 | $0 | $-66,775 | - |
| Gross Accounts Receivable | $467,528 | $352,838 | $327,174 | - |
| Cash Cash Equivalents And Short Term Investments | $11,075,871 | $6,571,610 | $8,912,517 | $6,176,866 |
| Cash And Cash Equivalents | $11,075,871 | $6,571,610 | $8,912,517 | $6,176,866 |
| Prepaid Assets | - | - | - | $797,225 |
| Debt | ||||
| Total Debt | $741,262 | $962,662 | $391,707 | $793,774 |
| Long Term Debt And Capital Lease Obligation | $305,755 | $644,865 | $15,994 | $389,498 |
| Current Debt And Capital Lease Obligation | $435,507 | $317,797 | $375,713 | $404,276 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,145,545 | $2,616,673 | $2,016,613 | $3,709,039 |
| Total Non Current Liabilities Net Minority Interest | $305,755 | $644,865 | $15,994 | $389,498 |
| Current Liabilities | $1,839,790 | $1,971,808 | $2,000,619 | $3,319,541 |
| Payables And Accrued Expenses | $913,878 | $1,165,733 | $1,066,430 | $2,776,145 |
| Payables | $370,142 | $626,190 | $544,179 | $1,666,068 |
| Accounts Payable | $370,142 | $626,190 | $544,179 | $1,166,068 |
| Current Deferred Liabilities | - | $0 | $16,171 | $0 |
| Other Payable | - | - | - | $500,000 |
| Equity | ||||
| Common Stock Equity | $13,434,495 | $9,206,109 | $12,089,727 | $9,078,541 |
| Total Equity Gross Minority Interest | $13,434,495 | $9,206,109 | $12,089,727 | $9,078,541 |
| Stockholders Equity | $13,434,495 | $9,206,109 | $12,089,727 | $9,078,541 |
| Gains Losses Not Affecting Retained Earnings | $128,569 | $128,569 | $128,569 | $128,569 |
| Other Equity Adjustments | $128,569 | $128,569 | $128,569 | $128,569 |
| Retained Earnings | $-117,237,892 | $-109,075,759 | $-101,400,209 | $-93,452,587 |
| Other | ||||
| Ordinary Shares Number | $2,002,186 | $445,947 | $166,409 | $32,533 |
| Share Issued | $2,002,186 | $445,947 | $166,409 | $32,533 |
| Tangible Book Value | $11,813,933 | $7,422,911 | $10,143,448 | $6,969,626 |
| Invested Capital | $13,434,495 | $9,206,109 | $12,089,727 | $9,078,541 |
| Working Capital | $11,027,489 | $6,717,777 | $9,331,108 | $6,278,235 |
| Capital Lease Obligations | $741,262 | $962,662 | $391,707 | $793,774 |
| Total Capitalization | $13,434,495 | $9,206,109 | $12,089,727 | $9,078,541 |
| Additional Paid In Capital | $39,322,644 | $35,368,899 | $35,741,115 | $31,684,098 |
| Capital Stock | $91,221,174 | $82,784,400 | $77,620,252 | $70,718,461 |
| Common Stock | $91,221,174 | $82,784,400 | $77,620,252 | $70,718,461 |
| Long Term Capital Lease Obligation | $305,755 | $644,865 | $15,994 | $389,498 |
| Current Capital Lease Obligation | $435,507 | $317,797 | $375,713 | $404,276 |
| Pensionand Other Post Retirement Benefit Plans Current | $490,405 | $488,278 | $542,305 | $139,120 |
| Current Accrued Expenses | $543,736 | $539,543 | $522,251 | $1,110,077 |
| Net PPE | $992,199 | $1,249,999 | $723,426 | $904,252 |
| Accumulated Depreciation | $-1,338,360 | $-1,355,311 | $-925,321 | $-516,470 |
| Gross PPE | $2,330,559 | $2,605,310 | $1,648,747 | $1,420,722 |
| Other Properties | $2,330,559 | $2,564,901 | $1,608,338 | $1,380,313 |
| Machinery Furniture Equipment | $0 | $40,409 | $40,409 | $40,409 |
| Finished Goods | $676,178 | $840,812 | $893,506 | $473,426 |
| Work In Process | $26,695 | $30,817 | $514,113 | $1,724,851 |
| Raw Materials | $258,300 | $372,695 | $208,737 | $292,577 |
| Foreign Currency Translation Adjustments | - | - | - | $128,569 |
| Leases | - | - | - | $40,409 |
| Properties | - | - | - | $0 |
| Other Short Term Investments | - | - | - | $44,804 |
Fetched: 2026-06-25
Cash Flow Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-7,766,951 | $-6,995,125 | $-7,445,003 | $-15,622,866 |
| Operating Activities | ||||
| Operating Cash Flow | $-7,766,951 | $-6,985,832 | $-7,283,199 | $-15,583,758 |
| Cash Flow From Continuing Operating Activities | $-7,766,950 | $-6,985,832 | $-7,283,199 | $-15,583,761 |
| Operating Gains Losses | $75,928 | $12,262 | $1,183 | $13,125 |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $-9,293 | $-661,804 | $-672,999 |
| Cash Flow From Continuing Investing Activities | $0 | $-9,293 | $-661,804 | $-672,999 |
| Capital Expenditure | - | $-9,293 | $-161,804 | $-39,108 |
| Net Other Investing Changes | - | - | - | $-425,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $8,130,299 | $5,216,194 | $10,680,008 | $17,146,114 |
| Financing Cash Flow | $12,271,212 | $4,654,218 | $10,680,654 | $15,070,497 |
| Cash Flow From Continuing Financing Activities | $12,271,212 | $4,654,218 | $10,680,654 | $15,070,497 |
| Net Other Financing Charges | $-883,978 | $-562,151 | $-1,319,782 | $-1,784,791 |
| Net Common Stock Issuance | $8,130,299 | $5,216,194 | $10,680,008 | $17,146,114 |
| Common Stock Issuance | $8,130,299 | $5,216,194 | $10,680,008 | $17,146,114 |
| Other | ||||
| Interest Paid Supplemental Data | $0 | $0 | $0 | $0 |
| Income Tax Paid Supplemental Data | $0 | $7,100 | $13,100 | $0 |
| End Cash Position | $11,075,871 | $6,571,610 | $8,912,517 | $6,176,866 |
| Beginning Cash Position | $6,571,610 | $8,912,517 | $6,176,866 | $7,363,126 |
| Changes In Cash | $4,504,261 | $-2,340,907 | $2,735,651 | $-1,186,260 |
| Proceeds From Stock Option Exercised | $5,024,891 | $175 | $646 | - |
| Net Investment Purchase And Sale | $0 | $0 | $0 | $0 |
| Sale Of Investment | $42,270 | $42,082 | $42,268 | $0 |
| Purchase Of Investment | $-42,270 | $-42,082 | $-42,268 | $0 |
| Net PPE Purchase And Sale | $0 | $-9,293 | $-161,804 | $-39,108 |
| Purchase Of PPE | $0 | $-9,293 | $-161,804 | $-39,108 |
| Change In Working Capital | $-337,167 | $-369,338 | $-565,821 | $-3,073,114 |
| Change In Other Current Liabilities | $-429,880 | $-397,422 | $-426,575 | $-341,862 |
| Change In Other Current Assets | $0 | $4,908 | $5,507 | $-61,432 |
| Change In Payables And Accrued Expense | $-249,728 | $45,282 | $-806,530 | $-811,599 |
| Change In Prepaid Assets | $173,980 | $20,284 | $299,192 | $190,661 |
| Change In Inventory | $283,151 | $66,220 | $565,561 | $-2,003,732 |
| Change In Receivables | $-114,690 | $-92,439 | $-219,147 | $-40,008 |
| Changes In Account Receivables | $-114,690 | $-92,439 | $-219,147 | $-40,008 |
| Other Non Cash Items | $-35 | $-1,250 | $-803 | $1,394,074 |
| Stock Based Compensation | $119,307 | $137,714 | $278,155 | $697,894 |
| Provisionand Write Offof Assets | $2,424 | $0 | $46,775 | $0 |
| Asset Impairment Charge | $0 | $305,812 | $308,937 | $3,472,593 |
| Depreciation Amortization Depletion | $534,725 | $604,518 | $595,997 | $511,787 |
| Depreciation And Amortization | $534,725 | $604,518 | $595,997 | $511,787 |
| Amortization Cash Flow | $162,636 | $171,858 | $202,249 | $159,228 |
| Amortization Of Intangibles | $162,636 | $171,858 | $202,249 | $159,228 |
| Depreciation | $372,089 | $432,660 | $393,748 | $352,559 |
| Net Foreign Currency Exchange Gain Loss | $75,928 | $12,262 | $1,183 | $1,770 |
| Net Income From Continuing Operations | $-8,162,133 | $-7,675,550 | $-7,947,622 | $-18,600,117 |
| Net Business Purchase And Sale | - | $0 | $-500,000 | $-208,891 |
| Purchase Of Business | - | $0 | $-500,000 | $-300,457 |
| Change In Other Working Capital | - | $-16,171 | $16,171 | $-5,142 |
| Repayment Of Debt | - | - | $0 | $-290,826 |
| Net Issuance Payments Of Debt | - | - | $0 | $-290,826 |
| Net Long Term Debt Issuance | - | - | $0 | $-290,826 |
| Long Term Debt Payments | - | - | $0 | $-290,826 |
| Sale Of Business | - | - | $0 | $91,566 |
| Effect Of Exchange Rate Changes | - | - | - | $0 |
| Sale Of PPE | - | - | - | - |
| Interest Received Cfo | - | - | - | - |
| Gain Loss On Investment Securities | - | - | - | - |
Fetched: 2026-06-25